Q3 2024 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Decreased by Analyst

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at Zacks Research lowered their Q3 2024 earnings per share estimates for Repligen in a report released on Tuesday, May 21st. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.33 for the quarter, down from their prior estimate of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. Zacks Research also issued estimates for Repligen’s Q1 2025 earnings at $0.44 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.46 EPS, FY2025 earnings at $1.96 EPS, Q1 2026 earnings at $0.65 EPS and FY2026 earnings at $2.81 EPS.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue was down 17.1% on a year-over-year basis.

Several other analysts have also weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. KeyCorp upped their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, Stifel Nicolaus raised their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Trading Down 3.8 %

NASDAQ:RGEN opened at $158.78 on Thursday. Repligen has a 52 week low of $110.45 and a 52 week high of $211.13. The firm’s fifty day moving average is $174.10 and its 200-day moving average is $177.17. The firm has a market cap of $8.87 billion, a P/E ratio of 635.15, a P/E/G ratio of 5.58 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.

Insider Buying and Selling at Repligen

In related news, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,296 shares of company stock valued at $7,550,643. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Repligen by 0.4% in the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after purchasing an additional 21,719 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in Repligen by 11.3% during the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after acquiring an additional 157,807 shares during the period. Brown Capital Management LLC lifted its position in shares of Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after acquiring an additional 83,416 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after acquiring an additional 29,215 shares during the period. Finally, Conestoga Capital Advisors LLC grew its position in shares of Repligen by 5.3% during the first quarter. Conestoga Capital Advisors LLC now owns 747,555 shares of the biotechnology company’s stock worth $137,490,000 after purchasing an additional 37,817 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.